CN103143024B - Implantable kidney-tonifying bone-invigorating traditional Chinese medicine extract-antibiotic-calcium sulfate sustained-release system, and preparation method and application thereof - Google Patents
Implantable kidney-tonifying bone-invigorating traditional Chinese medicine extract-antibiotic-calcium sulfate sustained-release system, and preparation method and application thereof Download PDFInfo
- Publication number
- CN103143024B CN103143024B CN201310056346.9A CN201310056346A CN103143024B CN 103143024 B CN103143024 B CN 103143024B CN 201310056346 A CN201310056346 A CN 201310056346A CN 103143024 B CN103143024 B CN 103143024B
- Authority
- CN
- China
- Prior art keywords
- antibiotic
- calcium sulfate
- kidney
- chinese medicine
- medicine extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明属于植入型缓释给药系统技术领域,尤其涉及一种补肾健骨中药提取物-抗生素-硫酸钙缓释系统及其制备方法和应用。该缓释系统按质量分计包括以下的组分:补肾健骨中药提取物0.1-1.0份,抗生素0.1-2.0份,硫酸钙载体5-20份,本发明有益效果在于药效维持时间长,具有中西医结合增效减毒作用,有效促进骨感染疾病的愈合,减低并发症,提高治愈率。
The invention belongs to the technical field of implantable sustained-release drug delivery systems, and in particular relates to a Chinese medicine extract-antibiotic-calcium sulfate sustained-release system for nourishing the kidney and strengthening bones and its preparation method and application. The slow-release system includes the following components in terms of mass: 0.1-1.0 parts of kidney-tonifying and bone-strengthening traditional Chinese medicine extract, 0.1-2.0 parts of antibiotics, and 5-20 parts of calcium sulfate carrier. It has synergistic and detoxifying effects of traditional Chinese and Western medicine, effectively promotes the healing of bone infection, reduces complications, and improves the cure rate.
Description
技术领域 technical field
本发明属于植入型缓释给药系统技术领域,尤其涉及一种补肾健骨中药提取物-抗生素-硫酸钙缓释系统及其制备方法和应用。 The invention belongs to the technical field of implantable sustained-release drug delivery systems, and in particular relates to a Chinese medicine extract-antibiotic-calcium sulfate sustained-release system for nourishing the kidney and strengthening bones and its preparation method and application.
背景技术 Background technique
骨髓炎等骨缺损合并骨感染疾病的发病率因社会发展呈上升趋势,治疗棘手,属外科领域亟待解决的疑难病种。临床治疗以手术清除病灶死骨与纤维化组织、继而实施组织瓣移植或骨移植,同时给予抗生素治疗为主。因静脉或口服抗菌药物很难进入感染深部杀灭细菌,且该病病程长,需长期使用抗菌药,必然增加抗生素用量以及治疗费用,同时易引发药物不良反应。因此,采用载抗生素植入材料进行局部缓释给药,既可发挥局部抗感染作用,又具缓释效果,且全身副作用较少,是目前临床常用治疗手段。早期的材料骨水泥(聚甲基丙烯酸甲酯,PMMA)曾倍受青睐,然而因需二次手术取出而逐渐被其他材料:如多聚乳酸及多聚乙醇酸、聚己酸内酯、羟基磷灰石与珊瑚羟基磷灰石复合物、胶原明胶、重组异种骨复合物、壳聚糖及其衍生物、脂质体、纳米材料、生物活性微晶玻璃等可吸收缓释材料替代,其中硫酸钙人工骨缓释系统使用广泛,该载体可以被新骨形成所利用,具较好的生物相容性及骨传导性,以及较低的抗生素用量和较短用药周期,成为目前骨髓炎治疗的主要植入载体。该载体的柱状结晶空间格局与抗生素形成良好的网状药物储库形态,植入体内后随载体的降解溶蚀释放所载药物,发挥缓释作用,持续维持较高的局部抗生素药物浓度。临床常用的抗生素如万古霉素、妥布霉素以及庆大霉素均适用于该载体,如中国发明专利申请(申请号:200510131093.2 申请日:2005-12-07)和中国发明专利申请(申请号:03148624.X 申请日:2003-06-23)。临床应用证实具有良好抑菌作用,但对骨质愈合作用不明显,并且高浓度抗生素可能对骨质愈合有抑制作用,因而临床治疗中骨愈合延迟(骨不连)的发生率较高。 The incidence of osteomyelitis and other bone defects combined with bone infection is on the rise due to social development, and the treatment is difficult. It is a difficult disease that needs to be solved urgently in the field of surgery. Clinical treatment is based on surgical removal of sequestrum and fibrotic tissue, followed by tissue flap transplantation or bone transplantation, and antibiotic treatment. Because it is difficult for intravenous or oral antibiotics to enter the deep part of the infection to kill bacteria, and the course of the disease is long, long-term use of antibiotics is required, which will inevitably increase the amount of antibiotics and treatment costs, and easily cause adverse drug reactions. Therefore, the use of antibiotic-loaded implant materials for local sustained-release administration can not only exert local anti-infection effects, but also have sustained-release effects, and have fewer systemic side effects. It is currently a commonly used clinical treatment. The early material bone cement (polymethyl methacrylate, PMMA) was once favored, but it was gradually replaced by other materials due to the need for secondary surgery: such as polylactic acid and polyglycolic acid, polycaprolactone, hydroxyl Apatite and coral hydroxyapatite complexes, collagen gelatin, recombinant heterogeneous bone complexes, chitosan and its derivatives, liposomes, nanomaterials, bioactive glass-ceramic and other absorbable and sustained-release materials instead, among which Calcium sulfate artificial bone sustained-release system is widely used. This carrier can be used by new bone formation, has good biocompatibility and osteoconductivity, as well as low antibiotic dosage and short drug cycle. It has become the current osteomyelitis treatment. main implant carrier. The space pattern of the columnar crystals of the carrier and the antibiotic form a good network drug storage shape, and after implantation in the body, the drug contained in it is released with the degradation and erosion of the carrier, exerting a slow-release effect, and continuously maintaining a high local antibiotic drug concentration. Commonly used clinical antibiotics such as vancomycin, tobramycin and gentamicin are suitable for this carrier, such as the Chinese invention patent application (application number: 200510131093.2 application date: 2005-12-07) and the Chinese invention patent application (application No.: 03148624.X Application date: 2003-06-23). Clinical application has proved to have a good antibacterial effect, but the effect on bone healing is not obvious, and high concentrations of antibiotics may have an inhibitory effect on bone healing, so the incidence of delayed bone healing (bone nonunion) in clinical treatment is relatively high.
现代研究证明多种补肾健骨中药均具有促进成骨细胞增殖作用。如淫羊藿苷、补骨脂及骨碎补等具有对OPG/RANK/RANKL以及TGF-β/BMPs信号通路的调控作用,诱导骨分化生长,促进骨生长愈合,发挥其成骨作用,并证实能够改善局部血液循环,通过经络系统的调节而起到纠正脏腑气血阴阳的偏盛偏衰,补虚泄实,改善全身状况。因此具有补肾健骨作用的中药,提取其有效组分即为补肾健骨中药提取物,此类中药包括淫羊藿、骨碎补、补骨脂、杜仲、牛膝、槲寄生、菟丝子等。当前尚无中药成分联合抗生素的硫酸钙缓释制剂应用于骨髓炎的实验研究及临床治疗。 Modern studies have proved that a variety of traditional Chinese medicines for invigorating the kidney and strengthening bones can promote the proliferation of osteoblasts. For example, icariin, psoralen and rhizoma drynaria can regulate OPG/RANK/RANKL and TGF-β/BMPs signaling pathways, induce bone differentiation and growth, promote bone growth and healing, and exert its osteogenic effect. It has been proved that it can improve local blood circulation, and correct the excess and decline of yin and yang of viscera, qi, blood, and yin and yang through the regulation of the meridian system, tonify deficiency and relieve excess, and improve the general condition. Therefore, the effective components of traditional Chinese medicines that have the function of nourishing the kidney and strengthening the bones are extracts of Chinese medicines for nourishing the kidney and strengthening the bones. At present, there is no calcium sulfate sustained-release preparation combined with traditional Chinese medicine ingredients and antibiotics for experimental research and clinical treatment of osteomyelitis.
发明内容 Contents of the invention
为了解决抗生素-载体给药体系存在的技术缺陷,本发明的第一个目的是提供一种植入型补肾健骨中药提取物-抗生素-硫酸钙缓释系统,该系统可能在抑菌同时促进骨质愈合,发挥增效减毒作用,有助于缩短骨愈合时间,降低骨不连的发生率,提高综合疗效。本发明的第二个目的是提供上述的缓释系统的制备方法。本发明的第三个目的是提供上述的缓释系统的应用。 In order to solve the technical defects of the antibiotic-carrier drug delivery system, the first object of the present invention is to provide an implantable kidney-tonifying and bone-strengthening traditional Chinese medicine extract-antibiotic-calcium sulfate slow-release system, which may promote bone growth while inhibiting bacteria. Quality healing, play synergistic and detoxifying effect, help to shorten the bone healing time, reduce the incidence of nonunion, and improve the comprehensive curative effect. The second object of the present invention is to provide a preparation method of the above-mentioned sustained-release system. The third object of the present invention is to provide the application of the above-mentioned slow-release system.
为了实现上述的第一个目的,本发明采用了以下的技术方案: In order to achieve the above-mentioned first purpose, the present invention adopts the following technical solutions:
一种植入型补肾健骨中药提取物-抗生素-硫酸钙缓释系统,该缓释系统按质量分计包括以下的组分: An implantable kidney-tonifying and bone-strengthening Chinese medicine extract-antibiotic-calcium sulfate slow-release system, the slow-release system includes the following components by mass fraction:
补肾健骨中药提取物 0.1-1.0份, 0.1-1.0 parts of traditional Chinese medicine extract for invigorating kidney and strengthening bones,
抗生素 0.1-2.0份, Antibiotics 0.1-2.0 copies,
硫酸钙载体 5-20份, Calcium sulfate carrier 5-20 parts,
作为优选,该缓释系统按质量分计包括以下的组分: Preferably, the slow-release system includes the following components by mass fraction:
补肾健骨中药提取物 0.1-0.3份, 0.1-0.3 copies of traditional Chinese medicine extract for invigorating the kidney and strengthening the bones,
抗生素 0.3-1.2份, Antibiotics 0.3-1.2 parts,
硫酸钙载体 8-10份, Calcium sulfate carrier 8-10 parts,
注射用水 0-4份。 Water for injection 0-4 parts.
作为优选,该缓释系统按质量分计还包括聚乳酸0-2份,海藻酸钠0-2份。 Preferably, the slow-release system further includes 0-2 parts of polylactic acid and 0-2 parts of sodium alginate in terms of mass fractions.
作为优选,所述的补肾健骨中药提取物选自淫羊藿总苷、骨碎补总黄酮、补骨脂总黄酮、牛膝总皂苷,菟丝子总黄酮和槲寄生总黄酮中的一种或多种混合。 Preferably, the Chinese medicine extract for invigorating the kidney and bone is selected from one or more of the total glycosides of icarii, the total flavonoids of drynariae, the total flavonoids of psoraleae, the total saponins of Achyranthes bidentata, the total flavonoids of Cuscuta chinensis and the total flavonoids of mistletoe Various mixes.
作为优选,所述的抗生素选自先锋Ⅳ、万古霉素、庆大霉素、妥布霉素、替考拉宁、头孢类和喹诺酮类中的一种或多种混合。 Preferably, the antibiotic is selected from one or more mixtures of Pioneer IV, vancomycin, gentamicin, tobramycin, teicoplanin, cephalosporins and quinolones.
作为优选,该缓释系统按质量分计由以下的组分构成:淫羊藿总苷0.1~0.3份,盐酸万古霉素粉针剂0.5~1.2份,硫酸钙8~10份,注射用水2~4份。 Preferably, the slow-release system is composed of the following components in terms of mass fractions: 0.1-0.3 parts of total icariin, 0.5-1.2 parts of vancomycin hydrochloride powder injection, 8-10 parts of calcium sulfate, and 2-2 parts of water for injection. 4 parts.
作为优选,该缓释系统按质量分计由以下的组分构成:淫羊藿总苷0.1~0.3份,硫酸妥布霉素注射液0.10~0.50份,海藻酸钠0.2~1.0份,硫酸钙8~10份。 Preferably, the slow-release system is composed of the following components in terms of mass fractions: 0.1-0.3 parts of icariin, 0.10-0.50 parts of tobramycin sulfate injection, 0.2-1.0 parts of sodium alginate, calcium sulfate 8~10 servings.
为了实现上述的第二个目的,本发明采用了以下的技术方案: In order to achieve the above-mentioned second purpose, the present invention adopts the following technical solutions:
一种制备上述任意一个技术方案所述的植入型补肾健骨中药提取物-抗生素-硫酸钙缓释系统的方法,该方法包括以下的步骤: A method for preparing the implantable kidney-tonifying and bone-strengthening traditional Chinese medicine extract-antibiotic-calcium sulfate slow-release system described in any one of the above technical solutions, the method comprises the following steps:
1)按处方比例,称取硫酸钙载体,置于洁净容器中,备用; 1) According to the prescription ratio, weigh the calcium sulfate carrier, put it in a clean container, and set aside;
2)按处方比例,称取补肾健骨中药提取物,备用; 2) According to the proportion of the prescription, weigh the Chinese medicine extract for invigorating the kidney and strengthening the bones, and set aside;
3)按处方比例,称取抗生素,如抗生素为液体制剂,则根据注射液标示量换算所需体积,按比例吸取抗生素,加入到步骤2)的补肾健骨中药提取物中,混合均匀成混合物或者溶解成澄明溶液,备用; 3) Weigh the antibiotic according to the proportion of the prescription. If the antibiotic is a liquid preparation, convert the required volume according to the marked amount of the injection, draw the antibiotic according to the proportion, add it to the Chinese medicine extract for nourishing kidney and strengthening bones in step 2), and mix well to form a mixture Or dissolve into a clear solution for later use;
4)如抗生素为固体制剂,则吸取灭菌生理盐水,加入到步骤3)的混合物中,溶解成澄明溶液,备用; 4) If the antibiotic is a solid preparation, draw sterilized physiological saline, add it to the mixture in step 3), dissolve into a clear solution, and set aside;
5)取步骤4)的澄明溶液,加入到步骤1)的载体材料中,快速搅拌均匀,立即以刮匙转移至相应模具中,填实并排除气泡,放置5-10min,完全固化后取出;即得补肾健骨中药提取物-抗生素-硫酸钙缓释制剂; 5) Take the clear solution in step 4), add it to the carrier material in step 1), stir quickly and evenly, transfer it to the corresponding mold immediately with a spatula, fill it up and remove air bubbles, leave it for 5-10 minutes, and take it out after it is completely cured; That is tonify the kidney and strengthen the bone Chinese medicine extract-antibiotic-calcium sulfate sustained-release preparation;
如抗生素为液体制剂,则直接取步骤3)的澄明溶液,加入到步骤1)的载体材料中,快速搅拌均匀,立即以刮匙转移至相应模具中,填实并排除气泡,放置5-10min,完全固化后取出;即得补肾健骨中药提取物-抗生素-硫酸钙缓释制剂。 If the antibiotic is a liquid preparation, directly take the clear solution in step 3), add it to the carrier material in step 1), stir quickly and evenly, transfer it to the corresponding mold with a spatula immediately, fill it up and remove air bubbles, and place it for 5-10min and take it out after being completely cured; the Chinese medicine extract-antibiotic-calcium sulfate sustained-release preparation for invigorating the kidney and strengthening the bones is obtained.
为了实现上述的第三个目的,本发明采用了以下的技术方案: In order to achieve the above-mentioned third purpose, the present invention adopts the following technical solutions:
上述任意一个技术方案所述的植入型补肾健骨中药提取物-抗生素-硫酸钙缓释系统用于制备治疗骨科骨感染或骨缺损疾病的药物中应用。 The implantable kidney-reinforcing and bone-strengthening traditional Chinese medicine extract-antibiotic-calcium sulfate slow-release system described in any one of the above technical solutions is used in the preparation of medicines for treating orthopedic bone infection or bone defect.
作为优选,上述任意一个技术方案所述的植入型补肾健骨中药提取物-抗生素-硫酸钙缓释系统用于制备治疗慢性骨髓炎的药物中应用。 Preferably, the implantable kidney-tonifying and bone-strengthening traditional Chinese medicine extract-antibiotic-calcium sulfate slow-release system described in any one of the above technical solutions is used in the preparation of medicines for treating chronic osteomyelitis.
本发明由于采用了上述的技术方案,具有以下优势: The present invention has the following advantages due to the adoption of the above-mentioned technical scheme:
1、采用中药-抗生素联合用药方式,制备具有缓释作用的植入性制剂,药效持续时间超过1个月,发挥抗生素抑菌和中药促进骨生长协同作用,持续发挥抗生素抑菌抗感染、中药促进骨质生长愈合作用,药效维持时间长,具有中西医结合增效减毒作用,有效促进骨感染疾病的愈合,减低并发症,提高治愈率;并且该缓释系统能够与其他药物组合,制备植入型缓释给药制剂; 1. Using the combination of traditional Chinese medicine and antibiotics to prepare implantable preparations with sustained release effect, the drug effect lasts for more than 1 month, exert the synergistic effect of antibiotic antibacterial and traditional Chinese medicine to promote bone growth, and continuously exert antibiotic antibacterial anti-infection, Traditional Chinese medicine promotes bone growth and healing, and the drug effect lasts for a long time. It has the synergistic and attenuating effect of integrated Chinese and Western medicine, effectively promotes the healing of bone infection, reduces complications, and improves the cure rate; and the sustained release system can be combined with other drugs , preparing an implantable sustained-release drug preparation;
2、以硫酸钙为载体,系统研究抗生素以及多种中药促骨成分与其相容性,制备植入型缓释给药制剂,采用扫描电镜、仪器分析等先进技术,分析制剂空间结构-溶蚀-药物释放-时间规律,制备符合临床需要的缓释制剂,为进一步的临床应用提供实验依据,发明内容具有良好的应用前景。 2. Using calcium sulfate as a carrier, systematically study the compatibility of antibiotics and bone-promoting components of various traditional Chinese medicines, prepare implantable sustained-release drug preparations, and use advanced technologies such as scanning electron microscopy and instrumental analysis to analyze the spatial structure of the preparations-erosion- Drug release-time rule, preparation of sustained-release preparations that meet clinical needs, provide experimental basis for further clinical application, and the invention content has good application prospects.
附图说明 Description of drawings
图1是本发明实施例提供的淫羊藿总苷-万古霉素-硫酸钙缓释系统体外模拟药物释放-时间曲线图。 Fig. 1 is an in vitro simulated drug release-time curve of the icariin-vancomycin-calcium sulfate sustained-release system provided by the embodiment of the present invention.
图2是本发明实施例提供的淫羊藿总苷-万古霉素-硫酸钙缓释系统对慢性骨髓炎兔的治疗作用比较图。 Figure 2 is a comparison chart of the therapeutic effect of the epimedium total glucosides-vancomycin-calcium sulfate sustained-release system provided by the embodiment of the present invention on chronic osteomyelitis rabbits.
具体实施方式 Detailed ways
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合附图及实施例,对本发明进行进一步详细说明。 In order to make the object, technical solution and advantages of the present invention clearer, the present invention will be further described in detail below in conjunction with the accompanying drawings and embodiments.
本发明实施例提供了一种植入型补肾健骨中药提取物-抗生素-硫酸钙缓释系统,该缓释系统的基础配方由如下所述的辅料按重量份数计制备得到: The embodiment of the present invention provides an implantable Chinese medicine extract-antibiotic-calcium sulfate slow-release system for invigorating the kidney and strengthening the bones. The basic formula of the slow-release system is prepared by the following auxiliary materials in parts by weight:
补肾健骨中药提取物0.1-1份,抗生素0.1-2份,聚乳酸0-2份,海藻酸钠0-2份,硫酸钙载体5-10份,注射用水0-5份。 0.1-1 part of traditional Chinese medicine extract for invigorating kidney and strengthening bones, 0.1-2 parts of antibiotics, 0-2 parts of polylactic acid, 0-2 parts of sodium alginate, 5-10 parts of calcium sulfate carrier, and 0-5 parts of water for injection.
该系统由上述给药系统的基础配方组成,其补肾健骨中药提取物以及抗生素涉及的成分如下: This system is composed of the basic formula of the above-mentioned drug delivery system. The ingredients involved in the kidney-tonifying and bone-reinforcing traditional Chinese medicine extract and antibiotics are as follows:
中药促骨成分:淫羊藿总苷,或骨碎补总黄酮,或补骨脂总黄酮,或牛膝总皂苷,或菟丝子总黄酮,或槲寄生总黄酮;抗生素:包括先锋Ⅳ、万古霉素、庆大霉素、妥布霉素、替考拉宁、头孢类以及喹诺酮类等。 Bone-promoting ingredients of traditional Chinese medicine: total icariin, or total flavonoids of drynariae, or total flavonoids of psoralen, or total saponins of Achyranthes bidentata, or total flavonoids of Cuscuta, or total flavonoids of mistletoe; antibiotics: including pioneer IV, vancomycin Factors such as gentamicin, tobramycin, teicoplanin, cephalosporins and quinolones.
本发明还确定了淫羊藿总苷-抗生素-硫酸钙缓释系统的最佳配方为: The present invention has also determined that the optimum formula of icariin-antibiotic-calcium sulfate slow-release system is:
淫羊藿总苷0.12g,盐酸万古霉素粉针剂0.9g,硫酸钙9.5g,注射用水3ml; Epimedium glycosides 0.12g, vancomycin hydrochloride powder injection 0.9g, calcium sulfate 9.5g, water for injection 3ml;
淫羊藿总苷0.12g,硫酸妥布霉素注射液0.12g(3ml),海藻酸钠0.6g,硫酸钙9.5g。 Epimedium glycosides 0.12g, Tobramycin Sulfate Injection 0.12g (3ml), Sodium Alginate 0.6g, Calcium Sulfate 9.5g.
实施例1Example 1
淫羊藿总苷-万古霉素-硫酸钙缓释制剂制备方法的操作步骤如下: The operation steps of the preparation method of icariin-vancomycin-calcium sulfate sustained-release preparation are as follows:
1)按处方比例,称取硫酸钙载体9.5g,置于洁净容器中,备用; 1) According to the proportion of the prescription, weigh 9.5g of calcium sulfate carrier, put it in a clean container, and set aside;
2)按处方比例,称取淫羊藿总苷(经含量测定,其中淫羊藿苷含量>10%)0.12g,备用; 2) According to the proportion of the prescription, weigh 0.12g of total icariin (the content of icariin is >10% after content determination) and set aside;
3)按处方比例,称取盐酸万古霉素粉针剂0.88g,加入到步骤2)的淫羊藿总苷中,混合均匀成混合物,备用; 3) According to the prescription ratio, weigh 0.88g of vancomycin hydrochloride powder injection, add it to the total icariin in step 2), mix well to form a mixture, and set aside;
4)吸取灭菌生理盐水3ml,加入到步骤3)的混合物中,溶解成澄明溶液,备用; 4) Draw 3ml of sterilized physiological saline, add it to the mixture in step 3), dissolve into a clear solution, and set aside;
5)取步骤4)的溶液,加入到步骤1)的载体材料中,快速搅拌均匀,立即以刮匙转移至相应模具中,填实并排除气泡,放置5-10min,完全固化后取出;即得淫羊藿总苷-万古霉素素-硫酸钙缓释制剂;测定含量,淫羊藿总苷含量为9.2mg/g(其中淫羊藿苷1.0mg/g),万古霉素含量为66.7mg/g。 5) Take the solution in step 4), add it to the carrier material in step 1), stir quickly and evenly, and immediately transfer it to the corresponding mold with a spatula, fill it up and remove air bubbles, place it for 5-10 minutes, and take it out after it is completely cured; Obtained icariin-vancomycin-calcium sulfate sustained-release preparation; measured content, total icariin content was 9.2mg/g (wherein icariin 1.0mg/g), vancomycin content was 66.7 mg/g.
实施例2Example 2
淫羊藿总苷-妥布霉素-硫酸钙缓释制剂制备方法的操作步骤如下: The operation steps of the preparation method of icariin-tobramycin-calcium sulfate sustained-release preparation are as follows:
1)按处方比例,称取硫酸钙载体9.5g,置于洁净容器中,备用; 1) According to the proportion of the prescription, weigh 9.5g of calcium sulfate carrier, put it in a clean container, and set aside;
2)按处方比例,称取淫羊藿总苷(经含量测定,其中淫羊藿苷含量>10%)0.12g,海藻酸钠0.6g,混合均匀,备用; 2) According to the proportion of the prescription, weigh 0.12g of total icariin (the content of icariin is >10% after content determination), 0.6g of sodium alginate, mix well, and set aside;
3)吸取硫酸妥布霉素3ml,加入到步骤2)的淫羊藿总苷与海藻酸钠混合物中,溶解,必要时进行超声促进溶解成澄明溶液,备用; 3) Take 3ml of tobramycin sulfate, add it to the mixture of icariin and sodium alginate in step 2), dissolve, and if necessary, conduct ultrasound to promote dissolution into a clear solution, and set aside;
4)取步骤3)的溶液,加入到步骤1)的载体材料中,快速搅拌均匀,立即以刮匙转移至相应模具中,填实并排除气泡,放置5-10min,完全固化后取出;即得淫羊藿总苷-妥布霉素-硫酸钙缓释制剂;测定含量,淫羊藿总苷含量为9.8mg/g(其中淫羊藿苷1.0mg/g),妥布霉素含量为9.8mg/g。 4) Take the solution in step 3), add it to the carrier material in step 1), stir quickly and evenly, and immediately transfer it to the corresponding mold with a spatula, fill it up and remove air bubbles, place it for 5-10 minutes, and take it out after it is completely cured; Obtained icariin-tobramycin-calcium sulfate sustained-release preparation; measured content, total icariin content is 9.8mg/g (wherein icariin 1.0mg/g), tobramycin content is 9.8 mg/g.
实施例3Example 3
实施例1的制剂用于慢性骨髓炎兔模型的局部植入给药,步骤包括: The preparation of Example 1 is used for local implant administration of chronic osteomyelitis rabbit model, and the steps include:
1)按处方比例,称取硫酸钙载体9.5g,置于洁净容器中,备用; 1) According to the proportion of the prescription, weigh 9.5g of calcium sulfate carrier, put it in a clean container, and set aside;
2)按处方比例,称取淫羊藿总苷(经含量测定,其中淫羊藿苷含量>35%)0.12g,备用; 2) According to the proportion of the prescription, weigh 0.12g of total icariin (the content of icariin is >35% after content determination) and set aside;
3)按处方比例,称取盐酸万古霉素粉针剂0.88g,加入到步骤2)的淫羊藿总苷中,混合均匀成混合物,备用; 3) According to the prescription ratio, weigh 0.88g of vancomycin hydrochloride powder injection, add it to the total icariin in step 2), mix well to form a mixture, and set aside;
4)吸取灭菌生理盐水3ml,加入到步骤3)的混合物中,溶解澄明溶液,备用; 4) Draw 3ml of sterilized physiological saline, add it to the mixture in step 3), dissolve the clear solution, and set aside;
5)取步骤4)的溶液,加入到步骤1)的载体材料中,快速搅拌均匀,立即以刮匙转移至相应模具中,填实并排除气泡,放置5-10min,完全固化后取出;即得淫羊藿总苷-万古霉素素-硫酸钙缓释制剂; 5) Take the solution in step 4), add it to the carrier material in step 1), stir quickly and evenly, and immediately transfer it to the corresponding mold with a spatula, fill it up and remove air bubbles, place it for 5-10 minutes, and take it out after it is completely cured; Obtain Epimedium glucosides-vancomycin-calcium sulfate sustained-release preparation;
6)取步骤5)的缓释制剂,进行空间显微结构分析、抗生素及中药指标成分的含量测定,测定结果:淫羊藿苷含量为4.2mg/g,万古霉素含量为86.3mg/g; 6) Take the sustained-release preparation in step 5), conduct spatial microstructure analysis, and determine the content of antibiotics and index components of traditional Chinese medicines. The measurement results: the content of icariin is 4.2 mg/g, and the content of vancomycin is 86.3 mg/g ;
7)取体重为2-2.5Kg的雄性新西兰兔,麻醉,采用胫骨打孔(孔径0.3cm)、接种金葡菌方式造模,2周后X射线检查结合血细菌培养,证实形成骨髓炎兔模型; 7) Take a male New Zealand rabbit with a weight of 2-2.5Kg, anesthetize it, make a hole in the tibia (hole diameter 0.3cm), and inoculate Staphylococcus aureus to make a model. After 2 weeks, X-ray examination combined with blood bacterial culture confirms the formation of osteomyelitis rabbits Model;
8)取步骤7)的兔模型,再次麻醉,彻底清创; 8) Take the rabbit model in step 7), anesthetize again, and thoroughly debride the wound;
9)取步骤5)的淫羊藿总苷-万古霉素-硫酸钙制剂3g,均匀放置于步骤8)的骨髓炎模型兔的创腔内,完成手术,创口埋置引流管,成为治疗模型兔;同时设模型对照组用于疗效比较; 9) Take 3 g of the icariin-vancomycin-calcium sulfate preparation in step 5), and place it evenly in the wound cavity of the osteomyelitis model rabbit in step 8), complete the operation, and embed a drainage tube in the wound to become a treatment model Rabbits; at the same time, a model control group was set up for curative effect comparison;
10)术后观察,病灶X影像学检测,局部药物浓度检测,根据病灶骨质生长情况、创口愈合情况评价疗效; 10) Postoperative observation, lesion X imaging detection, local drug concentration detection, evaluation of curative effect according to the bone growth of the lesion and wound healing;
11)术后2-10周内定期进行病灶X射线检查,与模型对照组相比,步骤9)的治疗模型图病灶骨质愈合时间缩短,血清骨钙素与血清碱性磷酸酶活性升高(见图2)。 11) The X-ray examination of the lesion was carried out regularly within 2-10 weeks after the operation. Compared with the model control group, the healing time of the lesion in the treatment model in step 9) was shortened, and the activities of serum osteocalcin and serum alkaline phosphatase were increased (See Figure 2).
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310056346.9A CN103143024B (en) | 2013-02-22 | 2013-02-22 | Implantable kidney-tonifying bone-invigorating traditional Chinese medicine extract-antibiotic-calcium sulfate sustained-release system, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310056346.9A CN103143024B (en) | 2013-02-22 | 2013-02-22 | Implantable kidney-tonifying bone-invigorating traditional Chinese medicine extract-antibiotic-calcium sulfate sustained-release system, and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103143024A CN103143024A (en) | 2013-06-12 |
| CN103143024B true CN103143024B (en) | 2014-06-25 |
Family
ID=48541525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310056346.9A Expired - Fee Related CN103143024B (en) | 2013-02-22 | 2013-02-22 | Implantable kidney-tonifying bone-invigorating traditional Chinese medicine extract-antibiotic-calcium sulfate sustained-release system, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103143024B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107586041B (en) * | 2017-10-27 | 2020-04-28 | 福州瑞克布朗医药科技有限公司 | Microcrystalline glass for dentistry and preparation method thereof |
| CN108578371B (en) * | 2018-05-16 | 2021-06-15 | 中国人民解放军南京军区福州总院四七六医院 | Streptomycin calcium sulfate sustained release preparation and preparation method thereof |
| CN111921002A (en) * | 2020-08-06 | 2020-11-13 | 湖北联结生物材料有限公司 | Antibacterial osteogenesis-promoting absorbable bone wax and preparation method thereof |
| CN114010838B (en) * | 2021-11-15 | 2022-08-23 | 中国人民解放军总医院第八医学中心 | Preparation method of composite bionic bone |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004060666B3 (en) * | 2004-12-15 | 2006-03-30 | Heraeus Kulzer Gmbh | Antibiotic-containing bone substitute material comprises a compacted mixture of antibiotic-containing mineral granules and a binder |
| CN1686557A (en) * | 2005-03-29 | 2005-10-26 | 天津大学 | Calcium sulphate based embedded type local medicine releasing system and preparation method |
| DE102006037362B3 (en) * | 2006-08-09 | 2007-09-20 | Heraeus Kulzer Gmbh | Bone-replacement material has calcium carbonate, which is suspended as particulate calcium carbonate in aqueous solution, which contains water soluble haemostatic agent |
| CN101195027A (en) * | 2006-12-06 | 2008-06-11 | 上海高科联合生物技术研发有限公司 | Application of lysostaphin in preparing medicament for treating osteomyelitis |
-
2013
- 2013-02-22 CN CN201310056346.9A patent/CN103143024B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103143024A (en) | 2013-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101520114B1 (en) | Fibrin compositions containing strontium compounds | |
| CN101668550B (en) | Premixed biological hydraulic cement paste composition and using the same | |
| Kong et al. | Mg-based bone implants show promising osteoinductivity and controllable degradation: a long-term study in a goat femoral condyle fracture model | |
| Huang et al. | Dual-delivery of vancomycin and icariin from an injectable calcium phosphate cement-release system for controlling infection and improving bone healing | |
| Mistry et al. | Treatment of long bone infection by a biodegradable bone cement releasing antibiotics in human | |
| WO2019048697A1 (en) | Macro- and microporous composite cryogel biomaterial for use in bone regeneration | |
| CN103143024B (en) | Implantable kidney-tonifying bone-invigorating traditional Chinese medicine extract-antibiotic-calcium sulfate sustained-release system, and preparation method and application thereof | |
| JP2010518946A (en) | Prevention and treatment of jaw osteonecrosis and jaw radiation osteonecrosis | |
| CN107660153A (en) | Biphase ceramics bone substitute | |
| TWI587881B (en) | Self-setting biodegradable bioactive bone graft putty material and application thereof | |
| CN101011601A (en) | Medicament-carrying complex calcium phosphate bone cement for spinal column reconstruction during tumour operation | |
| CN101820895A (en) | Compositions and methods for treating the spine | |
| Miao et al. | Multi-stage controllable degradation of strontium-doped calcium sulfate hemihydrate-tricalcium phosphate microsphere composite as a substitute for osteoporotic bone defect repairing: degradation behavior and bone response | |
| CN116194162A (en) | Methods and compositions for bone grafting using iron excipients | |
| Liu et al. | Controlling sustained statins release in multi-layered composite scaffolds for healing of osteoporotic bone defects | |
| Kwon et al. | Locally delivered ethyl-2, 5-dihydroxybenzoate using 3D printed bone implant for promotion of bone regeneration in a osteoporotic animal model | |
| Chen et al. | Calcium phosphate bone cements: their development and clinical applications | |
| Wang et al. | Effect of SDF-1 with biphasic ceramic-like bone graft on the repair of rabbit radial defect | |
| CN101816807B (en) | Bone repairing material for personalized treatment | |
| Nolff et al. | Comparison of computed tomography and microradiography for graft evaluation after reconstruction of critical size bone defects using β-tricalcium phosphate | |
| CN1326792C (en) | Calcium phoshate bone cement powder containing traditional Chinese medicine and its preparation method | |
| Chen et al. | Experimental study of a 3D-printing technique combined with biphasic calcium phosphates to treat osteonecrosis of the femoral head in a canine model | |
| CN103965510B (en) | Bone cement of controlled release high molecular weight protein and preparation method thereof | |
| CN101829354B (en) | Method for preparing microcapsule slow-release Chinese medicament complex calcium phosphate cement | |
| CN104815352A (en) | Magnesium sodium phosphate composite material and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140625 |